Compare ASND & BEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASND | BEN |
|---|---|---|
| Founded | 2006 | 1947 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.6B |
| IPO Year | 2015 | N/A |
| Metric | ASND | BEN |
|---|---|---|
| Price | $233.32 | $25.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $264.13 | $24.64 |
| AVG Volume (30 Days) | 638.0K | ★ 4.0M |
| Earning Date | 02-11-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | N/A | ★ 7.28 |
| EPS | N/A | ★ 0.91 |
| Revenue | $758,592,045.00 | ★ $8,770,700,000.00 |
| Revenue This Year | $99.54 | N/A |
| Revenue Next Year | $84.40 | $5.65 |
| P/E Ratio | ★ N/A | $28.08 |
| Revenue Growth | ★ 97.46 | 3.45 |
| 52 Week Low | $118.03 | $16.25 |
| 52 Week High | $238.84 | $26.25 |
| Indicator | ASND | BEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.45 | 59.78 |
| Support Level | $200.69 | $25.32 |
| Resistance Level | $238.84 | $25.84 |
| Average True Range (ATR) | 11.62 | 0.52 |
| MACD | 2.42 | -0.05 |
| Stochastic Oscillator | 88.16 | 67.73 |
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.